Condition
MAC Lung Disease
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
P 2 (1)
P 3 (2)
Trial Status
Terminated2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT03236987Phase 3Recruiting
CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections
NCT06418711Phase 3TerminatedPrimary
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
NCT05327803Phase 2TerminatedPrimary
Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
Showing all 3 trials